304360.KQ S.Biomedics Co. Ltd.
- Market cap
- KRW 238B
- P/E
- -
- P/B
- 7.91x
- ROE
- -60.7%
- Dividend yield
- -
- Fundamental score
- 1.3/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 304360.KQ undervalued?
Graham numberThe Graham number of S.Biomedics Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
S.Biomedics Co. Ltd. fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-60.7%), below 10%.
ROA 0/1
Return on assets (-24.2%) is below the industry median (-10.1%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-37.2%) is below the industry median (4.8%).
Revenue Growth 2/2
Revenue grew 11.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (45.1%), up to 100%.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 2/2
Cash covers 2.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (7.9x) is above the industry median (2.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
S.Biomedics Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the t…
Full company profileS.Biomedics Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
S.Biomedics Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 8.87B | 12.1B | 13.1B | 13.7B | 16.5B | 18.4B |
| Gross Profit | 4.32B | 6.11B | 6.55B | 6.71B | 7.55B | 9.37B |
| Operating Income | -4.63B | -3.74B | -5.95B | -5.28B | -8.34B | -13.4B |
| EBITDA | - | -2.97B | -6.70B | -3.24B | -3.32B | -10.7B |
| Net Income | -5.67B | -6.33B | -7.52B | -5.82B | -8.12B | -18.4B |
| EPS | -555 | -576 | -664 | -496 | -680 | -1,487 |
| Balance Sheet | ||||||
| Total Assets | 17.8B | 24.4B | 31.9B | 44.6B | 41.2B | 76.0B |
| Total Liabilities | 14.0B | 28.1B | 25.0B | 32.7B | 24.5B | 36.4B |
| Shareholders' Equity | 2.51B | -3.78B | 6.93B | 11.9B | 8.68B | 30.3B |
| Cash & Short-term Investments | 6.13B | 7.07B | 10.6B | 23.3B | 6.09B | 39.7B |
| Cash Flow | ||||||
| Operating Cash Flow | -3.29B | -3.21B | -6.15B | -3.50B | -3.98B | -11.0B |
| Capital Expenditure | 490M | 1.11B | 1.85B | 1.68B | 4.38B | 3.18B |
| Free Cash Flow | -3.78B | -4.31B | -8.00B | -5.18B | -8.36B | -14.2B |
| Ratios | ||||||
| ROE | -225.7% | - | -108.5% | -49.1% | -93.6% | -60.7% |
| ROA | -31.8% | -26.0% | -23.5% | -13.1% | -19.7% | -24.2% |
| Net Profit Margin | -63.9% | -52.2% | -57.4% | -42.4% | -49.1% | -99.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
S.Biomedics Co. Ltd. dividends
S.Biomedics Co. Ltd. has not paid dividends in the last 5 fiscal years.
Who owns S.Biomedics Co. Ltd.
- Insiders 22.44%
- Institutions 1.06%
- Public & others 76.50%
- Shares outstanding 12.4M
- Free float 9.62M
S.Biomedics Co. Ltd. company profile
- Company name
- S.Biomedics Co. Ltd.
- Ticker
- 304360.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 46
- Fiscal year end
- December
- Address
- Wooil Venture Town Building, Seoul, South Korea
- Phone
- 82 2 2205 0023
- Website
- sbiomedics.com
About S.Biomedics Co. Ltd.
S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products. The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.
S.Biomedics Co. Ltd. management
2- Dong-Wook KimCo-Chief Executive Officer
- SeIl KangCo- Chief Executive Officer